dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Glycine receptors (type: lgic)
Target: glycine receptor &alpha;3 subunit

Ligand: (12E,20Z,18S)-8-hydroxyvariabilin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.199999809265137 pIC50

Ligand: Cu2+ (Inorganic)
Interaction type: Allosteric modulator
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5 pIC50

Ligand: Δ9-tetrahydrocannabinol (Natural product)
Interaction type: Allosteric modulator
Action: Potentiation
Ligand approved: yes
Approval source: FDA (1985)
Primary target: no
Median affinity: 5.300000190734863 pEC50

Ligand: ginkgolide B (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 5.699999809265137 pIC50

Ligand: HU-210 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.300000190734863 pIC50

Ligand: nifedipine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: no
Median affinity: 4.5 pIC50

Ligand: onternabez (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7 pIC50

Ligand: picrotin (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 5.199999809265137 pIC50

Ligand: picrotoxin (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: picrotoxinin (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.400000095367432 pIC50

Ligand: strychnine (Natural product)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: [3H]strychnine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: WIN55212-2 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7 pIC50

Ligand: Zn2+ (Inorganic)
Interaction type: Allosteric modulator
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 3.799999952316284 pIC50
Target family: Glycine receptors (type: lgic)
Target: glycine receptor &beta; subunit

Ligand: bilobalide (Natural product)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 3.700000047683716 pIC50

Ligand: bilobalide (Natural product)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 4.300000190734863 pIC50

Ligand: cyanotriphenylborate (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 5.099999904632568 pIC50
Reference (Journal): Cyanotriphenylborate: subtype-specific blocker of glycine receptor chloride channels.
Published in: Proc Natl Acad Sci USA

Ligand: cyanotriphenylborate (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 5.599999904632568 pIC50
Reference (Journal): Cyanotriphenylborate: subtype-specific blocker of glycine receptor chloride channels.
Published in: Proc Natl Acad Sci USA

Ligand: ginkgolide B (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pIC50

Ligand: ginkgolide B (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pIC50

Ligand: ginkgolide B (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.300000190734863 pIC50

Ligand: ginkgolide X (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 3.5 pIC50

Ligand: ginkgolide X (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 3.5 pIC50

Ligand: nifedipine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: no
Median affinity: 5.900000095367432 pIC50

Ligand: nifedipine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: no
Median affinity: 4.900000095367432 pIC50

Ligand: picrotin (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 4.599999904632568 pIC50

Ligand: picrotin (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 4.599999904632568 pIC50

Ligand: picrotoxin (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 4.5 pIC50
Target family: Glycine receptors (type: lgic)
Target: glycine receptor &alpha;2 subunit

Ligand: 5,7-dichlorokynurenic acid (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Primary target: no
Median affinity: 3.700000047683716 pIC50

Ligand: bilobalide (Natural product)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.099999904632568 pIC50
Target family: Glycine transporter subfamily (type: transporter)
Target: GlyT2

Ligand: bitopertin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.519999980926514 pEC50
Reference (Journal): Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia.
Published in: J Med Chem
Target family: Glycine transporter subfamily (type: transporter)
Target: ATB<sup>0,+</sup>

Ligand: α-methyl-D,L-tryptophan (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 3.6 pIC50
Reference (Journal): Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapy.
Published in: Biochem J
Target family: Glycine transporter subfamily (type: transporter)
Target: GlyT2

Ligand: ALX 1393 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7 pIC50
Reference (Journal): Reversible inhibition of the glycine transporter GlyT2 circumvents acute toxicity while preserving efficacy in the treatment of pain.
Published in: Br J Pharmacol

Ligand: ALX 1405 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  -

Ligand: GT-0198 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.800000190734863 pIC50
Reference (Journal): Analgesic effect of GT-0198, a structurally novel glycine transporter 2 inhibitor, in a mouse model of neuropathic pain.
Published in: J Pharmacol Sci

Ligand: opiranserin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.070000171661377 pIC50
Reference (Journal): Safety, Tolerability, and Pharmacokinetic Characteristics of a Novel Nonopioid Analgesic, VVZ-149 Injections in Healthy Volunteers: A First-in-Class, First-in-Human Study.
Published in: J Clin Pharmacol

Ligand: Org 25543 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.800000190734863 pIC50
Reference (Journal): The first potent and selective inhibitors of the glycine transporter type 2.
Published in: J Med Chem
Target family: Glycine transporter subfamily (type: transporter)
Target: PROT

Ligand: compound 58 [PMID: 25037917] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.739999771118164 pIC50
Reference (Journal): Novel inhibitors of the high-affinity L-proline transporter as potential therapeutic agents for the treatment of cognitive disorders.
Published in: Bioorg Med Chem Lett

Ligand: LP-403812 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7 pIC50
Reference (Journal): Discovery and characterization of potent small molecule inhibitors of the high affinity proline transporter.
Published in: Neurosci Lett
Target family: Glycoprotein hormone receptors (type: gpcr)
Target: FSH receptor

Ligand: FSH (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1997)
Primary target: yes
Median affinity:  -

Ligand: FSH deglycosylated α/β (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 10 pKd
Reference (Journal): Recombinant deglycosylated human FSH is an antagonist of human FSH action in cultured rat granulosa cells.
Published in: Endocrinology Journal

Ligand: FSH deglycosylated α/β (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 10 pKd
Reference (Journal): Site-directed mutagenesis defines the individual roles of the glycosylation sites on follicle-stimulating hormone.
Published in: J Biol Chem

Ligand: [125I]FSH (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: Glycoprotein hormone receptors (type: gpcr)
Target: TSH receptor

Ligand: [125I]TSH (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: Glycoprotein hormone receptors (type: gpcr)
Target: LH receptor

Ligand: hCG (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Absence of exon 10 of the human luteinizing hormone (LH) receptor impairs LH, but not human chorionic gonadotropin action.
Published in: J Clin Endocrinol Metab

Ligand: hCG (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Expression of human luteinizing hormone (LH) receptor: interaction with LH and chorionic gonadotropin from human but not equine, rat, and ovine species.
Published in: Mol Endocrinol

Ligand: LH (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (2004)
Primary target: yes
Median affinity:  pIC50
Reference (Journal): Expression of human luteinizing hormone (LH) receptor: interaction with LH and chorionic gonadotropin from human but not equine, rat, and ovine species.
Published in: Mol Endocrinol

Ligand: LH (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (2004)
Primary target: yes
Median affinity:  pIC50
Reference (Journal): Absence of exon 10 of the human luteinizing hormone (LH) receptor impairs LH, but not human chorionic gonadotropin action.
Published in: J Clin Endocrinol Metab

Ligand: [125I]chorionic gonadotropin (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: [125I]LH (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: Glycoprotein hormone receptors (type: gpcr)
Target: TSH receptor

Ligand: compound 8b [PMID: 22408719] (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.739999771118164 pEC50
Reference (Journal): The Synthesis and Evaluation of Dihydroquinazolin-4-ones and Quinazolin-4-ones as Thyroid Stimulating Hormone Receptor Agonists.
Published in: Medchemcomm

Ligand: TSH (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1953)
Primary target: yes
Median affinity:  -
Target family: Gonadotrophin-releasing hormone receptors (type: gpcr)
Target: GnRH<sub>1</sub> receptor

Ligand: [Ac-D-2Nal1,D4CPA2,D-3Pal3,6,Leu8, D-Ala10]GnRH-II (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.180000305175781 pIC50
Reference (Journal): GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.
Published in: Cancer Res
Target family: Gonadotrophin-releasing hormone receptors (type: gpcr)
Target: GnRH<sub>2</sub> receptor

Ligand: trptorelix-1 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): GnRH-II analogs for selective activation and inhibition of non-mammalian and type-II mammalian GnRH receptors.
Published in: Mol Cells

Ligand: GnRH II (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.970000267028809 pIC50
Reference (Journal): A novel mammalian receptor for the evolutionarily conserved type II GnRH.
Published in: Proc Natl Acad Sci USA

Ligand: GnRH I (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 7.369999885559082 pIC50
Reference (Journal): A novel mammalian receptor for the evolutionarily conserved type II GnRH.
Published in: Proc Natl Acad Sci USA

Ligand: GnRH I (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 7.369999885559082 pIC50
Reference (Journal): Gonadotropin-releasing hormone receptors.
Published in: Endocr Rev
Target family: GPR18, GPR55 and GPR119 (type: gpcr)
Target: <i>GPR55</i>

Ligand: JWH015 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.4 pEC50
Reference (Journal): The orphan receptor GPR55 is a novel cannabinoid receptor.
Published in: Br J Pharmacol
Target family: GRK4 subfamily (type: enzyme)
Target: G protein-coupled receptor kinase 5

Ligand: compound 1o [PMID: 24210504] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.230000019073486 pIC50
Reference (Journal): Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors.
Published in: Bioorg Med Chem Lett
Target family: GRK4 subfamily (type: enzyme)
Target: G protein-coupled receptor kinase 4

Ligand: balanol (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.590000152587891 pIC50
Reference (Journal): Structure of human G protein-coupled receptor kinase 2 in complex with the kinase inhibitor balanol.
Published in: J Med Chem
Target family: GRK4 subfamily (type: enzyme)
Target: G protein-coupled receptor kinase 6

Ligand: balanol (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.309999942779541 pIC50
Reference (Journal): Structure of human G protein-coupled receptor kinase 2 in complex with the kinase inhibitor balanol.
Published in: J Med Chem
Target family: GSK subfamily (type: enzyme)
Target: glycogen synthase kinase 3 beta

Ligand: alsterpaullone 2-cyanoethyl (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.100000381469727 pIC50
Reference (Journal): A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Published in: Proc Natl Acad Sci USA
Target family: GSK subfamily (type: enzyme)
Target: glycogen synthase kinase 3 alpha

Ligand: GSK-3 inhibitor X (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.
Published in: J Med Chem
Target family: GSK subfamily (type: enzyme)
Target: glycogen synthase kinase 3 alpha

Ligand: rucaparib metabolite M324 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.239999771118164 pIC50
Reference (Journal): Identification of differential biological activity and synergy between the PARP inhibitor rucaparib and its major metabolite.
Published in: Cell Chem Biol

Ligand: aloisine A (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.300000190734863 pIC50
Reference (Journal): Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
Published in: J Med Chem

Ligand: AZD1080 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.15999984741211 pKi
Reference (Journal): AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans.
Published in: J Neurochem

Ligand: CHIR-98014 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.1899995803833 pIC50
Reference (Journal): Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo.
Published in: Diabetes

Ligand: GSK-3 inhibitor IX (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.300000190734863 pIC50
Reference (Journal): Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.
Published in: J Med Chem

Ligand: GSK-3 inhibitor IX (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.300000190734863 pIC50
Reference (Journal): GSK-3-selective inhibitors derived from Tyrian purple indirubins.
Published in: Chem Biol
Target family: GSK subfamily (type: enzyme)
Target: glycogen synthase kinase 3 beta

Ligand: alsterpaullone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.399999618530273 pIC50
Reference (Journal): Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.
Published in: Eur J Biochem

Ligand: 7-hydroxystaurosporine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.300000190734863 pIC50
Reference (Journal): Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide.
Published in: Mol Cancer Ther

Ligand: 1-azakenpaullone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.739999771118164 pIC50
Reference (Journal): 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta.
Published in: Bioorg Med Chem Lett
Target family: GSK subfamily (type: enzyme)
Target: glycogen synthase kinase 3 alpha

Ligand: voruciclib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.769999980926514 pIC50
Reference (Journal): Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells.
Published in: PLoS ONE

Ligand: SB-415286 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.420000076293945 pIC50
Reference (Journal): Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription.
Published in: Chem Biol

Ligand: SB 216763 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.050000190734863 pIC50
Reference (Journal): Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription.
Published in: Chem Biol

Ligand: laduviglusib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.010000228881836 pIC50
Reference (Journal): Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo.
Published in: Diabetes
Target family: Haemoglobin degradation pathway enzymes (type: other_protein)
Target: Plasmodium falciparum heme detoxification protein

Ligand: Lys01 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.349999904632568 pIC50
Reference (Journal): Potent Antimalarial Activity of Two Arenes Linked with Triamine Designed To Have Multiple Interactions with Heme.
Published in: ACS Med Chem Lett

Ligand: Lys01 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pIC50
Reference (Journal): Potent Antimalarial Activity of Two Arenes Linked with Triamine Designed To Have Multiple Interactions with Heme.
Published in: ACS Med Chem Lett
Target family: Haem oxygenase (type: enzyme)
Target: Haem oxygenase 1

Ligand: compound 1 [PMID: 16821802] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.099999904632568 pIC50
Reference (Journal): Imidazole-dioxolane compounds as isozyme-selective heme oxygenase inhibitors.
Published in: J Med Chem

Ligand: compound 1 [PMID: 16821802] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.820000171661377 pKi
Reference (Journal): Imidazole-dioxolane compounds as isozyme-selective heme oxygenase inhibitors.
Published in: J Med Chem
Target family: Haem oxygenase (type: enzyme)
Target: Haem oxygenase 2

Ligand: compound 1 [PMID: 16821802] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 3.5199999809265137 pIC50
Reference (Journal): Imidazole-dioxolane compounds as isozyme-selective heme oxygenase inhibitors.
Published in: J Med Chem
Target family: Haspin family (type: enzyme)
Target: histone H3 associated protein kinase

Ligand: SGI-1776 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.46999979019165 pIC50
Reference (Journal): Potential use of selective and nonselective Pim kinase inhibitors for cancer therapy.
Published in: J Med Chem
Target family: Heat shock proteins (type: other_protein)
Target: TNF receptor associated protein 1

Ligand: luminespib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.800000190734863 pIC50
Target family: Heat shock proteins (type: other_protein)
Target: heat shock protein family A (Hsp70) member 5

Ligand: cerebral dopamine neurotrophic factor (Peptide)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -